(Q83207666)

English

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

scientific article published on 01 June 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

based on heuristic

inferred from title

Claude Preudhomme

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

François Guilhot

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Catherine Roche-Lestienne

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Nicolini FE

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Corm S

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Lê QH

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sorel N

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Hayette S

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Bories D

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Leguay T

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Roy L

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Giraudier S

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tulliez M

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Facon T

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Mahon FX

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Cayuela JM

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Rousselot P

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Michallet M

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1061-1066

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to imatinib: mechanisms and implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

An activating mutation in the ATP binding site of the ABL kinase domain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404236

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404236

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642048%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83207666&oldid=2221352061"